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Tay-Sachs disease belongs to the group of autosomal-recessive lysosomal storage
metabolic disorders. This disease is caused by β-hexosaminidase A (HexA) enzyme
deficiency due to various mutations in α-subunit gene of this enzyme, resulting in
GM2 ganglioside accumulation predominantly in lysosomes of nerve cells. Tay-Sachs
disease is characterized by acute neurodegeneration preceded by activated microglia
expansion, macrophage and astrocyte activation along with inflammatory mediator
production. In most cases, the disease manifests itself during infancy, the “infantile
form,” which characterizes the most severe disorders of the nervous system. The
juvenile form, the symptoms of which appear in adolescence, and the most rare form
with late onset of symptoms in adulthood are also described. The typical features of
Tay-Sachs disease are muscle weakness, ataxia, speech, and mental disorders. Clinical
symptom severity depends on residual HexA enzymatic activity associated with some
mutations. Currently, Tay-Sachs disease treatment is based on symptom relief and, in
case of the late-onset form, on the delay of progression. There are also clinical reports
of substrate reduction therapy using miglustat and bone marrow or hematopoietic
stem cell transplantation. At the development stage there are methods of Tay-Sachs
disease gene therapy using adeno- or adeno-associated viruses as vectors for the
delivery of cDNA encoding α and β HexA subunit genes. Effectiveness of this approach
is evaluated in α or β HexA subunit defective model mice or Jacob sheep, in which
Tay-Sachs disease arises spontaneously and is characterized by the same pathological
features as in humans. This review discusses the possibilities of new therapeutic
strategies in Tay-Sachs disease therapy aimed at preventing neurodegeneration and
neuroinflammation.
Keywords: lysosomal storage diseases, GM2-gangliosidosis, β-hexosaminidase, Tay-Sachs disease,
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INTRODUCTION
GM2-gangliosidoses are a group of autosomal-recessive lysosomal storage disorders (LSDs). These
diseases result from a deficiency of lysosomal enzyme β-hexosaminidase (Hex), which is responsible
for GM2 ganglioside degradation (Ferreira and Gahl, 2017). Gangliosides are the main glycolipids
of neuronal cell plasma membranes which ensure normal cellular activities (Sandhoff and Harzer,
2013). There are two major β-hexosaminidase isoenzymes: HexA consists of two subunits, α and β;
HexB is a homodimer consisting of two β-subunits (Ferreira and Gahl, 2017). The two subunits of
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HexA enzyme, α and β, are synthesized at the endoplasmic
reticulum (ER) where glycosylation, the formation of
intramolecular disulfide bonds and dimerization take place
(Weitz and Proia, 1992; Maier et al., 2003). Besides HexA and
HexB isoenzymes a homodimer consisting of two α-subunits,
called HexS, is also found (Hou et al., 1996).
After the dimerization of subunits in ER, β-hexosaminidase
is transported to the Golgi complex, where it undergoes
post-translational modification. The most important of these is
the addition of mannose-6-phosphate (M6P) to the side chains
of the oligosaccharide (Sonderfeld-Fresko and Proia, 1989). The
residues of phosphorylated mannose can be considered as an
address mark recognized by specific receptors found on the inner
surface of the Golgi complex’s membranes. With the aid of this
mark a lysosome recognizes the enzyme and absorbs it (Weitz
and Proia, 1992).
Inside lysosomes α and β subunits are proteolytically
processed into a mature form (Hubbes et al., 1989). Also in
the lysosome, the presentation of the GM2 ganglioside substrate
from the bilayer to the HexA active site requires the presence of
GM2 activator protein (GM2A) (Martino et al., 2002b; Cachon-
Gonzalez et al., 2006). GM2A a co-factor and is necessary in order
to make lipophilic GM2 ganglioside available for hydrolysis in
the hydrophilic medium of the lysosome (Renaud and Brodsky,
2016; Sandhoff, 2016; Figure 1). HexA and HexB can hydrolyze
a wide range of substrates with terminal N-acetylglucosamine
residues (GlcNAc) to β-bonds. Only the HexA isoenzyme can
interact with a GM2 ganglioside-GM2A complex (Lemieux et al.,
2006). Although only HexA hydrolyzes GM2 ganglioside, both
isoenzymes can hydrolyze glycoproteins, glycosaminoglycans,
and glycolipids (Ferreira and Gahl, 2017).
HexA, HexB, and HexS in the absence of GM2A
can also hydrolyze synthetic substrates, for example, 4-
methylumbelliferone-GlcNAc fluorescent substrate (4MUG).
Another compound related to 4MUG is 4-methylumbelliferyl-
GlcNAc-6-sulfate (4MUGS) which is only hydrolyzed by
isoenzymes HexA and HexS. These compounds are used in
GM2-gangliosidoses diagnosis and detection of HEXA and
HEXB gene mutation carriers (Cachon-Gonzalez et al., 2012).
The HexA enzyme is a product of HEXA and HEXB genes
that encode, respectively, the α and β subunits, the amino acid
sequence identity of which is about 60% (Mark et al., 2003; Dersh
et al., 2016).
PATHOGENESIS OF
GM2-GANGLIOSIDOSIS
GM2-gangliosidosis can be caused by mutations in three genes:
HEXA (15th chromosome), HEXB (5th chromosome), and
GM2A (5th chromosome) (Mahuran, 1999; Ferreira and Gahl,
2017). GM2-gangliosidosis includes (I) Tay-Sachs disease (TSD,
OMIM 272800), at which mutations occur in the HEXA gene and
only HexA activity is disrupted (variant B); (II) Sandhoff disease
(SD; OMIM 268800), caused by mutations in HEXB gene, at
which the activity of HexA and HexB is disrupted (variant O); and
(III) GM2 activator protein deficiency (OMIM 272750), at which
mutations take place in the GM2A gene (variant AB) (Mahuran,
1999).
In patients with HexA deficiency GM2 ganglioside
accumulates inside lysosomes, which form characteristic
inclusions within the cells, so called membranous cytoplasmic
bodies, which are enlarged lysosomes filled with gangliosides
(Ferreira and Gahl, 2017; Figure 1). The highest concentration
of GM2 ganglioside is found in neuronal cells, therefore, the
HexA deficiency primarily affects the nervous system, causing
mental and motor developmental delay in patients (Myerowitz,
1997). Later, progressive destruction of neurons, proliferation of
microglia and accumulation of complex lipids in macrophages
are observed in the brain tissue. A similar process develops in the
neurons of the cerebellum, basal ganglia, brain stem, spinal cord,
spinal ganglia, and also in neurons of the autonomic nervous
system. Ganglion cells in the retina also swell and contain GM2
gangliosides, particularly, along the edges of the macula. As a
result, a cherry red spot appears in the macula and emphasizes
the normal color of the actual choroid, contrasting with the pale,
swollen ganglion cells in the affected part of the retina (Ferreira
and Gahl, 2017).
An inflammatory response is also observed in patients with
GM2-gangliosidosis. Wada et al. (2000) offered a model of
acute neurodegeneration in GM2-gangliosidosis and showed that
massive death of neurons is preceded by activated microglia
expansion. The activation of macrophages and astrocytes along
with inflammatory mediators production is also observed
(Myerowitz et al., 2002). This inflammatory response can occur
before the clinical manifestation of symptoms and aggravates the
neurological dysfunction (Wu and Proia, 2004).
In the CNS of GM2-gangliosidosis mouse model, microglial
cell activation, and infiltration of inflammatory cells are also
observed (Jeyakumar et al., 2003). Hayase et al. (2010) showed
that TSD patient cerebrospinal fluid has significantly increased
levels of TNF-α pro-inflammatory cytokine, which is involved in
the induction of inflammatory response. The authors suggested
that an increase in TNF-α level indicates inflammation in the
CNS and may contribute to disease progression (Hayase et al.,
2010). Utz et al. (2015) identified five possible inflammatory
biomarkers ENA-78, MCP-1, MIP-1α, MIP-1β, and TNFR2,
increased levels of these in the cerebrospinal fluid is associated
with infantile gangliosidosis.
TAY-SACHS DISEASE
Tay-Sachs disease is caused by mutations in the HEXA
gene. The incidence of this disease is one in 100,000 live
births (carrier frequency of about one in 250) (Lew et al.,
2015). TSD, SD, and GM2A deficiency are clinically similar
(Seyrantepe et al., 2018). More than 130 different mutations in
HEXA gene are described (partial deletion, splicing mutations,
nonsense mutations, missense mutations) leading to disruption
of transcription, translation, folding, dimerization of monomers
and catalytic dysfunction of HexA protein (Myerowitz, 1997;
Sakuraba et al., 2006; Mistri et al., 2012). TSD heterogeneity
in severity of clinical symptoms and the age at disease
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FIGURE 1 | Pathogenesis of Tay-Sachs disease.
onset is determined by residual HexA enzymatic activity that
occurs with some mutations (Kaback and Desnick, 1993). Only
10–15% of HexA activity is required in order to prevent the
accumulation of GM2 ganglioside (Osher et al., 2015). The
three different forms of TSD are classified by severity of clinical
symptoms and the age of onset (Patterson, 2013).
Clinical symptoms and course of the infantile form of TSD,
which occurs more often than others, are the most studied.
The infantile form, which is characterized by onset around
6 months of age and very low HexA activity levels (<0.5%),
rapidly manifests with mental and motor developmental delay
(Sandhoff and Christomanou, 1979). In the most severe infantile
forms symptoms may occur a few months after childbirth
(Nestrasil et al., 2018). Common neurodegenerative symptoms
in infants are hypotension, inability to sit or hold their head
unsupported, eye movement abnormalities, dysphagia, spasms,
and hypomyelination (Jarnes Utz et al., 2017). Most patients with
the infantile TSD do not survive past 4 years of age (Bley et al.,
2011).
The juvenile form of the disease strikes in early childhood,
usually at the age of 3–10 years. Common symptoms are ataxia,
dysarthria, dysphagia development, hypotension, and spasm
progression. Most patients do not live past the age of 15 years
(Nestrasil et al., 2018). In adolescent patients the disease is less
severe but has a wider range of symptoms (Regier et al., 2016).
Common symptoms are limb muscle weakness and abnormal
gait which are observed in 88% of patients (Maegawa et al.,
2006).
In contrast to the infantile and juvenile forms, the later-onset
form is less aggressive, characterized by small mutations and
higher residual activity level of HexA, which is 5–20% of normal
activity. Symptoms typically appear in adolescence or early
adulthood, but can appear later (20–30 years) (Sandhoff and
Christomanou, 1979). Therefore, neurodegeneration progression
is slowed presenting with delayed onset and gradual decline in
motor, cerebral and spinocerebellar function (Deik and Saunders-
Pullman, 2014; Osher et al., 2015).
Currently there are several therapy approaches to these
diseases, including substrate reduction (Bembi et al., 2006),
bone marrow transplantation (Jacobs et al., 2005), hematopoietic
(Stepien et al., 2017) or neural stem cell transplantation
(Gonzalez et al., 2016), use of anti-inflammatory drugs (Hayase
et al., 2010), administration of purified enzyme (Tsuji et al., 2011),
and gene therapy to restore expression of a dysfunctional protein
(Cachon-Gonzalez et al., 2012).
TSD MODELS
To investigate the efficacy of new TSD therapies Liu and Zhao
(2016) proposed an in vitro model of induced pluripotent stem
cells (iPSCs) derived from infantile TSD patient fibroblasts.
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These cells expressed OCT4, SOX2, NANOG, Tra-1-60, and
alkaline phosphatase pluripotency factors and had the ability to
differentiate into tissues from all three germ layers (Liu and Zhao,
2016).
The main in vivo models of TSD include mice and sheep. The
first mouse TSD model was created in 1995 by knockout of the
HEXA gene. This line of mice lacked HexA activity, however,
GM2 ganglioside accumulation and membrane cytoplasmic body
formation in neurons occurred only in certain regions of the
brain, excluding the olfactory bulb, the cerebral cortex and the
anterior horn of the brain. Also, HEXA knockout mice had a
normal lifespan and no clinical symptoms of TSD (Taniike et al.,
1995). A number of other studies show that HEXA-defective mice
exhibit biochemical and pathological features of TSD without
obvious neurological dysfunction (Cohen-Tannoudji et al., 1995;
Sango et al., 1995). The difference in the distribution of neuronal
storage delineates a difference in ganglioside metabolism between
humans and mice. It was shown that mice have one or more
sialidases that remove sialic acid from GM2 ganglioside, which
can later be hydrolyzed by HexB in HEXA-deficient TSD model
mice (Yuziuk et al., 1998; Seyrantepe et al., 2018).
In contrast to HEXA-deficient mice HEXB-deficient TSD
mice, develop CNS neurodegeneration, with spasticity, muscle
weakness, rigidity, tremor, and ataxia (Sango et al., 1995; Phaneuf
et al., 1996). Thus HEXB-deficient mice can be useful for the
initial evaluation of potential GM2-gangliosidosis treatment.
A strain of mice deficient in HEXA and sialidase NEU3
genes have been developed with a lifespan of 1.5–4.5 months
(Seyrantepe et al., 2018). An abnormal accumulation of
GM2 ganglioside in the brains of these mice and the
presence of membrane cytoplasmic bodies in neurons
were found. HEXA/NEU3-deficient mice have progressive
neurodegeneration, bone structure anomalies, and neurologic
abnormalities such as ataxia, tremor and slow movement. The
described pathologies and symptoms in HEXA/NEU3-deficient
mice mimic those observed in patients with early onset TSD.
This strain of mouse is a suitable model to investigate new TSD
therapies (Seyrantepe et al., 2018).
Tay-Sachs disease is also described in other animal species, for
example flamingo Phoenicopterus ruber (Zeng et al., 2008) and
Jacob sheep (Torres et al., 2010). In these species TSD develops
spontaneously and is characterized by HexA enzymatic activity
deficiency and GM2 ganglioside accumulation (Lawson and
Martin, 2016). It was shown that the nucleotide and amino acid
sequences identity of the coding region ofHEXA gene in flamingo
and humans is about 70% (Zeng et al., 2008). However, a serious
interspecies difference limits the use of flamingos as a model to
investigate pathogenesis and therapy of human TSD. In terms
of research, one of the most useful species with spontaneously
developing TSD is a Jacob sheep. Torres et al. (2010) showed
that in Jacob sheep, TSD clinical manifestations are closest to the
pathological features in humans. Sheep with TSD also suffered
from ataxia, proprioceptive defects and cortical blindness (Porter
et al., 2011). Genetic studies showed that HexA activity deficiency
in these sheep is associated with a single nucleotide substitution
in exon 11 of the HEXA gene, which leads to glycine-to-arginine
substitution (Torres et al., 2010).
SUBSTRATE REDUCTION THERAPY
Substrate reduction therapy (SRT) utilizes small molecules to
slow the rate of glycolipid biosynthesis (Platt et al., 2003).
Efficacy of miglustat (N-butyldeoxynojirimycin, NB-DNJ) in the
prevention of GM2 ganglioside accumulation was demonstrated
in TSD murine models (Platt et al., 1997; Bembi et al.,
2006). NB-DNJ is a small iminosugar competitive inhibitor of
glucosylceramide synthase. It catalyzes the first committed step
of glycosphingolipid synthesis and can penetrate the blood-brain
barrier (Boomkamp et al., 2010). It has been shown that
that NB-DNJ added to the food of TSD model mice reduces
GM2 ganglioside accumulation in the brain by 50% (Platt
et al., 1997). Bembi et al. (2006) assessed the clinical efficacy
of NB-DNJ in two patients with TSD infantile form. The
authors observed a significant concentration of NB-DNJ in the
cerebrospinal fluid of the patients. The use of SRT did not
stop the neurologic dysfunction progression in patients, however,
the authors recommend the use of NB-DNJ for macrocephaly
prevention (Bembi et al., 2006). Similar results were described in
a clinical trial (NCT00672022) in five patients (Maegawa et al.,
2009).
ENZYME REPLACEMENT THERAPY
The development of enzyme replacement therapy (ERT) is a
promising option for the treatment of lysosomal storage diseases.
After ERT therapy many somatic symptoms are decreased, but
it is less effective in preventing CNS neurodegeneration since
intravenous administration doesn’t allow the enzyme molecule
to cross the blood-brain barrier (Jakobkiewicz-Banecka et al.,
2007; Sorrentino et al., 2013). ERT is clinically approved for the
following diseases: Gaucher disease (Barton et al., 1991; Connock
et al., 2006), Fabry disease (Eng et al., 2001), Pompe disease
(Klinge et al., 2005), and mucopolysaccharidosis type I (Wraith
et al., 2004), type II (Muenzer et al., 2002) and type VI (Harmatz
et al., 2004).
The major challenge in creating HexA-based ERT is the
need to synthesize both of the enzyme subunits (Tropak
et al., 2016). Methylotrophic yeast Ogataea minuta (Om)
culture, simultaneously expressing the HEXA and HEXB
genes, can be used for the production of recombinant HexA
enzymes. The purified HexA was treated with α-mannosidase to
expose mannose-6-phosphate (M6P) residues on the N-glycans
(Akeboshi et al., 2007; Tsuji et al., 2011). The therapeutic efficacy
of recombinant HexA was demonstrated in the SD mouse
model (hexb−/− mice) and improvement of motor function,
increase of survival rate and inhibition of the induction of
MIP-1α were noted (Tsuji et al., 2011). Tropak et al. (2016)
created a hybrid µ subunit combining the critical characteristics
of α and β HexA subunits. The hybrid µ subunit contains
an active α subunit site, a stable β subunit interface, and
unique regions of each subunit necessary for interaction with
GM2A. To purify the HexM µ-homodimer HEK239 cells
with CRISPR deleted HEXA and HEXB genes and also stably
expressing the µ subunit were used. The authors showed that,
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in combination with GM2A, HexM hydrolyzes the derivative
of GM2-ganglioside both in cellulo and in vitro (Tropak et al.,
2016).
Matsuoka et al. (2011) modified the nucleotide sequence
of the human HEXB gene encoding the chimeric β subunit
to contain the partial amino acid sequence of the α subunit.
Chinese hamster ovary (CHO) cell lines were modified with the
chimeric HEXB gene to obtain a cell line with the chimeric HexB
stable expression. It was shown that chimeric HexB can degrade
artificial anionic substrates and GM2 ganglioside in vitro, and
also maintain the thermal stability of the wild-type HexB enzyme
in plasma. In TSD patient derived fibroblasts it was shown
that the treatment of cells with the chimeric HexB led to the
incorporation of the enzyme into the cells and the degradation
of the accumulated GM2-ganglioside. Intracerebroventricular
administration of chimeric HexB to SD model mice restored
Hex activity in the brain and reduced the accumulation of
GM2-ganglioside in the parenchyma (Matsuoka et al., 2011).
BONE MARROW TRANSPLANTATION
Jacobs et al. (2005) published the clinical case of the application of
bone marrow transplantation (BMT) with the following substrate
reduction therapy to treat the patient with TSD. The use of BMT
and Zavesca R© (miglustat) led to an increase in HexA activity in
leukocytes and plasma 23 months after transplantation, but did
not prevent the development of neurological dysfunction.
A case of BMT from a HLA-matched sibling to a 15-year-old
patient with late-onset TSD has been described where 8 years
after BMT complete graft retention remained unchanged. HexA
activity in leukocytes was 187 nmol/mg/h, which is comparable
to the enzyme activity in control group leukocytes. HexA activity
in plasma was 15 nmol/mg/h, which is three times lower than the
lower limit of HexA normal activity (50–250 nmol/mg/h). There
was also no intentional tremor progression after BMT (Stepien
et al., 2017).
There are cases of BMT in in vivo studies on SD mouse models
which showed that BMT prolongs the survival rate (from 4.5
to 8 months) (Norflus et al., 1998) and improves neurologic
manifestations in laboratory animals (Wada et al., 2000).
An alternative approach for patients who do not have a
suitable bone marrow donor is transplantation of hematopoietic
stem cells from umbilical cord blood obtained from partially
HLA-matched unrelated donors (Martin et al., 2006). Human
umbilical cord blood is an important source of stem cells and
progenitor cells capable of providing neuroprotective effect in
degenerative disease caused by various factors. Transplantation
of umbilical cord blood cells is considered to be a promising
approach to treat neurodegenerative disease in ischemic or
traumatic spinal cord injury (Galieva et al., 2017).
GENE THERAPY
Attempts to correct mutations in HEXA gene by gene and
cell engineering began in the mid-1990s. The first vectors for
the delivery of wild-type HEXA gene were adenoviruses. Akli
et al. (1996) first produced TSD patient skin-derived fibroblasts
expressing the HEXA gene by adenovirus transduction. The
enzyme activity in the transduced fibroblasts was 40–84% of the
norm. The secretion level of an enzyme α-subunit was 25 times
higher than the patient’s untreated control fibroblasts (Akli et al.,
1996).
In vivo studies with HEXA knockout mice showed that in
case of intravenous co-administration, HEXA and HEXB gene
expressing adenoviral vectors preferentially transduced liver cells.
Delivery of both HexA subunits promoted enzyme secretion
in the serum, as well as the enzymatic activity restoration in
peripheral tissues (Guidotti et al., 1999). The main limiting factor
for successful use of adenoviral vectors in CNS disease treatment
is the inability to overcome the blood-brain barrier (Gray et al.,
2010). Another disadvantage is the immunogenicity of adenoviral
vectors and their tropism to liver cells which leads to a high
accumulation of the vector and overexpression of the transgene in
this organ which risks development of hepatocellular carcinoma
(Nakamura et al., 2003).
Guidotti et al. (1998) also constructed a retroviral vector
encoding the human HEXA gene cDNA and produced a
stable line of hexa−/− mouse fibroblasts with overexpression of
the human HEXA gene. The resulting fibroblast line secreted
the interspecies HexA enzyme: human α-subunit and mouse
β-subunit. The cultivation of fibroblasts with HexA deficiency
in the culture medium from transduced fibroblasts resulted in
restoration of intracellular HexA activity in non-transduced cells.
Absorption of the enzyme by non-transduced fibroblasts from
the culture medium was the result of receptor-mediated transfer
analagous to lysosomal uptake of the enzyme. Thus HexA can
pass from the overexpressing cell to neighboring cells that have a
receptor essential for recognizing of M6P (Guidotti et al., 1998).
This method based on the ability of non-transduced cells to take
up the enzyme is termed cross-correction.
The possibility of cross-correction to restore the metabolism
of gangliosides in TSD patient-derived fibroblasts in vitro has
been investigated. A stable NIH3T3 mouse fibroblast cell line
with HEXA gene overexpression was made using retroviral
transduction. It was shown that when cultured in transduced
NIH3T3 cells conditioned medium TSD-fibroblasts absorbed
a large amount of soluble enzyme, however, there was not a
sufficient amount of the enzyme necessary for the degradation of
GM2 ganglioside in lysosomes (Martino et al., 2002b). Therefore,
the cross-correction-based delivery of HexA is insufficient to
change the phenotype of TSD-fibroblasts.
The major challenges in TSD gene therapy are the choice
of the vector and delivery method of therapeutic genes in
order to overcome the blood-brain barrier along with minimal
side effects (Kyrkanides et al., 2005). Martino et al. (2005)
proposed an in vivo gene transfer strategy for the production
and distribution of the HEXA gene in the CNS in TSD model
animals. A replication-defective herpes simplex virus type 1
(HSV-1) encoding HEXA gene cDNA was made. HSV-1 is able
to infect various types of non-dividing cells, including neurons,
and is transferred in a retrograde fashion to motor and/or sensory
neuron bodies after peripheral inoculation (Wolfe et al., 1999).
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It was shown that the injection of HSV-1-HEXA into the
inner capsule of the left cerebral hemisphere of TSD model
mice restored HexA activity. GM2 ganglioside accumulation
disappeared both in the injected and in the control (right)
hemispheres, as well as in the cerebellum and spinal cord of the
studied animals within a month after the injection (Martino et al.,
2005). Thus when the viral vector is directly delivered to the
brain of laboratory animals, a high efficiency of cell transduction
is shown. However, due to the large size of a human brain, this
approach has limitations for the uniform distribution of the viral
vector throughout the central nervous system and would require
a large number of injections.
Great progress has been achieved in developing approaches for
GM2 gangliosidoses gene therapy using adeno-associated virus
(AAV)-based vectors (Gray-Edwards et al., 2018). Intracranial
administration of recombinant AAV (rAAV) serotypes 2/1 or 2/2
encoding the HEXA and HEXB gene cDNA to SD model mice
led to a wide spread of HexA in the nervous system without
apparent cytotoxicity associated with rAAV use and an increase in
mouse survival rate (Cachon-Gonzalez et al., 2006, 2012). Defects
in myelination occur at an early age and so there are time limits
within which gene therapy can lead to positive results and slow
the progression of neurological worsening (Cachon-Gonzalez
et al., 2014).
Adeno-associated virus-based vectors are limited in their
capacity (from 2.1 to 4.5 kb) and cannot carry the cDNA of both
HEXA and HEXB genes, and the efficiency of co-transduction is
significantly less than transduction with a single construct. This
is a limiting factor in the application of these vectors since the
effective recovery of the secretion of the absent heterodimeric
HexA isoenzyme requires the expression of both subunits, α
and β (Tropak et al., 2016). Tropak et al. (2016) designed
the self-complementary AAV9.47 encoding a hybrid µ subunit
(scAAV9.47-HEXM) and showed that intracranial injection of
scAAV9.47-HEXM decreased GM2 ganglioside accumulation
in the brain of TSD model mice. Intravenous administration
of scAAV9.47-HEXM to newborn TSD model mice showed a
long-term decrease in GM2 ganglioside accumulation in the
CNS and a decreased distribution of this vector in the liver
compared to AAV9, AAVrh10 or AAVrh8 (Karumuthil-Melethil
et al., 2016). Intravenous injection of scAAV9.47-HEXM results
in effective transduction of CNS cells and an 2.5-fold increase
in survival rate of newborn SD model mice compared with the
control group (Osmon et al., 2016).
The therapeutic efficacy of AAVrh8-based gene therapy on the
Jacob sheep TSD model has been studied. Sheep aged 2–4 months
received intracranial injections of only AAVrh8 encoding α
subunit (AAVrh8-HEXA), or two vectors encoding α or β subunit
(AAVrh8-HEXA + AAVrh8-HEXB). It was shown that all sheep
after AAV injection had a delay in the appearance of symptoms
and/or a decrease in the acquired symptoms of the disease. When
AAVrh8-HEXA + AAVrh8-HEXB were injected, an excellent
distribution of HexA in the sheep brain was noted, unlike the
injection of AAVrh8-HEXA. However, HexA distribution in
the sheep spinal cord was low in all groups and a decrease in the
activation and proliferation of microglia in the sheep brain after
gene therapy was noted (Gray-Edwards et al., 2018). The data
were confirmed by studies with SD cats that demonstrated safety
and a wide spread of Hex in the CNS, after intracranial injection
of AAVrh8 encoding the species-specific α and β Hex subunits
(Bradbury et al., 2013).
A study of the safety of AAVrh8 encoding the α and β
Hex subunit of normal cynomolgus macaques (cm) showed that
dyskinesia, ataxia, and loss of dexterity developed in most of
the monkeys with intracranial injection of AAVrh8-cmHexα/β
(Golebiowski et al., 2017). Animals that received a high dose
of AAVrh8-cmHexα/β eventually became apathetic. The time of
symptom onset depended on the dose, with the highest dose
causing symptoms within a month after the infusion. Histological
analyses showed severe necrosis of white and gray matter
along the injection pathway, the reactive vasculature and the
presence of neurons with granular eosinophilic material. Despite
neurotoxicity, a sharp increase in Hex activity was noted in the
thalamus (Golebiowski et al., 2017). The authors suggested that
severe neurotoxicity may be associated with Hex overexpression.
The data about TSD gene therapy are generalized in Table 1.
GENETICALLY MODIFIED MULTIPOTENT
CELLS
The transplantation of ex vivo modified multipotent neural cells
(MNCs) in the CNS is another therapeutic strategy. An MNC
line with human HEXA gene overexpression (MNCs-HEXA)
has been produced by retroviral transduction Lacorazza et al.
(1996). MNCs-HEXA stably secreted the biologically active
HexA enzyme and cross-corrected the metabolic defect in TSD
patient-derived fibroblast culture in vitro. Intracranial injection
of MNCs-HEXA to mice resulted in expression of a significant
quantity of the human HexA subunit transcript and active HexA
enzyme production (Lacorazza et al., 1996). It has been shown
that transduction of stromal cells obtained from the bone marrow
of TSD model mice, with retrovirus encoding HEXA gene cDNA,
results in an increase in secretion of the active HexA enzyme
capable of hydrolyzing GM2 ganglioside (Martino et al., 2002a).
TREATMENT STRATEGIES FOR
LYSOSOMAL STORAGE DISORDERS
Currently, the number of available treatments for patients with
LSDs is increasing. For example, BMT (Lange et al., 2006;
Rovelli, 2008), SRT (Coutinho et al., 2016), and ERT (Li,
2018) are used for therapy of Gaucher disease, Fabry disease,
mucopolysaccharidoses (MPS), Pompe disease, Niemann-Pick
disease, etc. ERT and SRT methods are approved for these
diseases in Europe, United States, and other countries (Beck,
2018). The previously described drug Zavesca R© is also used for
the treatment of Niemann-Pick disease type C (Hassan et al.,
2018; Pineda et al., 2018) and GM1-gangliosidosis (Deodato
et al., 2017). It is worth mentioning that, similarly to TSD, early
diagnosis is necessary for successful LSD therapy in order to
prevent organ damage that aggravates the disease progression
(Wasserstein et al., 2018).
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TABLE 1 | In vivo investigations of Tay-Sachs disease gene therapy effectiveness.
Vector Gene Model Injection method Result Reference
Recombinant
adenovirus
HEXA HEXB HEXA knockout
mice
Intravenously HexA secretion in the serum and enzymatic
activity restoration in peripheral tissues.
Preferential transduction of liver cells is
observed
Guidotti et al., 1999
HSV-1 HEXA TSD model mice Intracranial to the
inner capsule of the
left cerebral
hemisphere
High efficiency of cell transduction, HexA
activity restoration and removal of GM2
ganglioside accumulation in both hemispheres
of the brain
Martino et al., 2005
rAAV 2/1 or 2/2 HEXA HEXB SD model mice Intracranial Wide spread of HexA in the nervous system
and increased survival rate
Cachon-Gonzalez
et al., 2006, 2012,
2014
scAAV9.47 HEXM TSD model mice Intracranial Reduction of GM2 accumulation in the brain of
mice
Tropak et al., 2016
scAAV9.47 HEXM TSD model
newborn mice
Intravenously Long-term decrease in GM2 ganglioside
accumulation in the CNS and decrease in
biodistribution of the vector in the liver
Karumuthil-Melethil
et al., 2016
scAAV9.47 HEXM SD model newborn
mice
Intravenously Reduction of GM2 accumulation in the CNS, an
2.5-fold increase in the survival rate of mice
Osmon et al., 2016
AAVrh8 HEXA HEXB TSD Jacob sheep Intracranial Delay in the symptom manifestation and/or a
decrease in the acquired symptoms, decrease
in the activation and proliferation of microglia in
the sheep brain. Low HexA distribution in the
spinal cord was noted
Gray-Edwards
et al., 2018
AAVrh8 HEXA HEXB SD cats Intracranial Safety and wide spread of Hex in the CNS Bradbury et al.,
2013
AAVrh8 HEXA HEXB Normal
cynomolgus
macaques
Intracranial A sharp increase in Hex activity. The
development of neurotoxicity, presumably due
to Hex overexpression
Golebiowski et al.,
2017
TABLE 2 | Efficacy of various therapeutic approaches for TSD treatment in pre-clinical and clinical trials.
Therapeutic
approach
Small animal models Large animal models Clinical trials/case reports in TSD
patients
Substrate reduction
therapy
Miglustat was shown to prevent the GM2
ganglioside accumulation in the brain of
TSD model mice (Platt et al., 1997; Bembi
et al., 2006)
N/A Use of miglustat did not stop the neurologic
dysfunction progression (NCT00672022)
(Maegawa et al., 2009). SRT is
recommended for macrocephaly prevention
(Bembi et al., 2006)
Enzyme
replacement
therapy
Improvement of motor function and
increased survival rate in SD model mice
(Matsuoka et al., 2011; Tsuji et al., 2011)
N/A No registered clinical trials available
Bone marrow
transplantation
Increased from 4.5 to 8 months survival
rate in SD model mice, improvement of
neurological manifestations (Norflus et al.,
1998; Wada et al., 2000)
N/A Only case reports available: HexA activity
increase. Neurologic dysfunction
progression was not stopped (Jacobs
et al., 2005; Stepien et al., 2017)
Gene therapy (see
Table 1 for more
detailed
information)
HexA activity restoration and removal of
GM2 ganglioside accumulation in CNS and
increased survival rate in SD or TSD model
mice
Safety and wide spread of HexA in the CNS
in SD cats. TSD Jacob sheep delay in the
symptom manifestation and inflammation
reduction in CNS were observed. In normal
cynomolgus macaques the development of
neurotoxicity in response to gene therapy
drug injection is shown
No registered clinical trials available
Administration of
multipotent cells
genetically modified
with HexA
HexA activity increase after injection to mice
(Lacorazza et al., 1996)
N/A No registered clinical trials available
Lifelong prescription of ERT with recombinant
glucocerebrosidase showed good results in the treatment of
Gaucher disease. ERT stops the main clinical manifestations of
the disease, improves the quality of life of patients and has no
pronounced adverse effects (Zimran et al., 2018). However, for
some LSDs, such as MPSI, II and VI, Pompe disease and diseases
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with CNS damage, ERT is not effective as the large molecules of
recombinant enzymes are unable to penetrate damaged tissues
to achieve therapeutic levels (Wraith, 2006; Begley et al., 2008;
Parenti et al., 2013).
Non-TSD LSDs caused by missense mutations and small
deletions without frameshift can be treated with the use of
small molecules of pharmacological chaperones to increase active
enzyme concentration (Pereira et al., 2018). If the mutation does
not affect the active or binding site of the enzyme and only leads
to disruption of the protein conformation then pharmacological
chaperones can be used as protein stabilizers to form a stable
structure and maintain catalytic activity (Parenti, 2009). The
molecular chaperones thereby increase the intracellular pool of
active enzymes and can partially restore metabolic homeostasis.
The application of this approach is under investigation for
Gaucher disease (Goddard-Borger et al., 2012), Fabry disease
(Kato et al., 2010), Pompe disease (Porto et al., 2009), and Krabbe
disease (Berardi et al., 2014).
For many LSDs gene therapy approaches [comprehensively
discussed in the review (Biffi, 2016)] as well as genome editing
techniques using zinc-finger nucleases (ZFN) for MPSI and
MPSII (Harmatz et al., 2018) are being actively explored.
Improvement of LSD treatment methods, in particular, using
pharmacological chaperones and genome editing technologies
can also contribute to the development of new approaches to
TSD treatment which is important since the current approved
treatment options for this disease have low efficiency.
CONCLUSION
To achieve a therapeutic effect in the treatment of TSD the
production and distribution of the absent HexA enzyme in
CNS is required. SRT, ERT, and BMT showed low efficacy to
prevent neurodegeneration in the CNS although these methods
can partially restore HexA activity and reduce GM2 ganglioside
accumulation in cells (Table 2). It is important to remember
that in order to achieve the maximum therapeutic effect, it
is necessary to start TSD therapy from the time of its early
manifestations, since myelination defects appear at early stages
and are aggravated with time.
Currently there are methods of TSD gene therapy being
developed using viral vectors for the delivery of cDNA of
encoding α and β HexA subunit genes. In humans, it is necessary
for viral vectors to successfully cross the blood-brain barrier since
the injection of genetic constructs directly into the CNS is not
feasible due to the large size of the human brain. In addition,
severe neurotoxic effects due to HexA overexpression in case of
direct viral delivery to the brain of cynomolgus macaques gives
rise to concern.
Of particular interest are studies using the scAAV9.47 vector
encoding the HEXM gene of the hybrid µ subunit that contains
the α subunit active site, the stable β subunit interface, and
also the unique regions in each subunit that are required for
interaction with GM2A. This vector is able to cross the blood-
brain barrier and the HEXM gene circumvents the capacity
limitation of AAV vectors. However, studies of the efficacy of this
viral construction are currently limited to in vivo experiments in
TSD or SD model mice.
Further investigation of the therapeutic potential of genetically
modified stem cells is important, since in addition to restoring
the activity of the deficient enzyme, these cells can have a
neuroprotective effect to limit the degenerative processes that
are observed in TSD patients. This, combined with stem cells
can prevent the activation of microglia guarding against further
neurodegeneration.
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